leisure time -WSS

leisure time

author：Wikipedia 2025-09-05 13:47:28 - browse：632

This image provided by Amylyx Pharmaceuticals shows the drug Relyvrio. The maker of a much-debated drug for Lou Gehrig’s disease said Friday, March 8, 2024 its therapy failed to help patients in a large follow-up study, but stopped short of committing to follow through on a prior pledge to pull the drug from the U.S. market. — Relyvrio, an ALS drug made by Amylyx Pharmaceuticals, failed to beat placebo in a key clinical trial. Amylyx Pharmaceuticals via AP

The latest disappointment in amyotrophic lateral sclerosis research brought crushing news for patients and physicians, forcing the community to consider just what to do with an approved medicine that doesn’t appear to work.

Amylyx Pharmaceuticals’ announcement Friday that its drug, marketed as Relyvrio, failed to beat placebo in a pivotal study marks “a sad day for us, but we have to believe the data,” said Mary Catherine Collet, an ALS advocate. “These are hard scientific facts that we have to face, and I appreciate that they’re not trying to spin us like some cheerleading practice.”

The question now is whether Relyvrio, approved in 2022, should be removed from the market entirely — and whether the Food and Drug Administration made a mistake by authorizing it in the first place. After years of pressure from patient advocates, the agency has taken a more flexible approach to medicines for devastating, incurable diseases like ALS. But the case of Relyvrio, which made $381 million in sales and $49 million in profit for Amylyx last year, has underlined questions about the limits of regulatory leniency.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： What Mike Pence has said that could be used in a Donald Trump trial

explore

WSS

Sutter Health’s antitrust win overturned by appeals court

ASCO Takeaways: Winners, snoozers, and the art of cancer care

Wild otter attack leads to woman being airlifted to hospital, 2 others treated for injuries

How CO2 helps viruses stay alive longer in the air

Anthony Fauci pushes back on GOP claims during Covid hearing

Fight over Supreme Court dialysis ruling puts kidney patients at risk

hotspot

leisure time

entertainment

As demand for Covid shots wanes, Moderna seeks its next success

CMS got Medicare Advantage quality rating wrong, judge rules

George Santos makes 1st court appearance after pleading not guilty to 13 counts

TytoCare raises $49 million to build out AI

Psychedelics group wrestles with new pharma identity

Eli Lilly’s Zepbound improved liver scarring in mid

Medical leaders decry Supreme Court decision on affirmative action

Illumina board agrees to spin off Grail, as divestment plans proceed

Drug repurposing or repositioning? The language matters

Congress needs to close a vaccine

knowledge

Senators tussle over abortion against the backdrop of a presidential campaign

Influencer to be charged after chaos erupts in New York City's Union Square

2 US Navy sailors arrested for allegedly spying for China

'Little Tech' descents on D.C., wanting a say in how AI is regulated

'Ancient DNA,' 23andMe reveal African American ancestries

Anthony Fauci pushes back on GOP claims during Covid hearing

explore

knowledge

focus

focus